Home/Filings/4/0001628280-25-010115
4//SEC Filing

Konidaris Tasos 4

Accession 0001628280-25-010115

CIK 0001723128other

Filed

Mar 3, 7:00 PM ET

Accepted

Mar 4, 6:59 PM ET

Size

8.8 KB

Accession

0001628280-25-010115

Insider Transaction Report

Form 4
Period: 2025-03-01
Konidaris Tasos
Executive Vice President & CFO
Transactions
  • Exercise/Conversion

    Restricted Stock Units

    2025-03-0136,1970 total
    Class A Common Stock (36,197 underlying)
  • Tax Payment

    Class A Common Stock

    2025-03-01$8.67/sh13,494$116,993550,019 total
  • Exercise/Conversion

    Class A Common Stock

    2025-03-01+36,197563,513 total
Footnotes (4)
  • [F1]Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.
  • [F2]Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
  • [F3]Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.
  • [F4]On March 1, 2021, the reporting person was granted 144,788 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

Issuer

Amneal Pharmaceuticals, Inc.

CIK 0001723128

Entity typeother

Related Parties

1
  • filerCIK 0001320982

Filing Metadata

Form type
4
Filed
Mar 3, 7:00 PM ET
Accepted
Mar 4, 6:59 PM ET
Size
8.8 KB